Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) 'Quantum BioPharma' or the 'Company') a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that management will attend the Sidoti Micro-Cap Conference and the A.G.P. Virtual Healthcare Conference in May 2025.
Quantum BioPharma Head of Finance and M&A Jason Sawyer will attend the Sidoti Micro-Cap Conference on May 21 and the A.G.P. Virtual Healthcare Conference on May 22, where Mr. Sawyer is scheduled to host one-on-one meetings with institutional investors at both events and host a webcast presentation at the Sidoti Micro-Cap Conference.
Sidoti Micro-Cap Conference Date: Wednesday, May 21, 2025Format: Presentation & Virtual 1x1 MeetingsPresentation: 9:15-9:45 AM ET in Track 1Webcast: Click hereAttendee: Head of Finance and M&A Jason SawyerConference Website: Click here
A.G.P. Virtual Healthcare ConferenceDate: Thursday, May 22, 2025Format: Virtual 1x1 MeetingsAttendee: Head of Finance and M&A Jason SawyerConference Website: Click here
For more information on the Sidoti Micro-Cap Conference, A.G.P. Virtual Healthcare Conference, or to schedule a one-on-one meeting with Quantum BioPharma management, please contact your conference representative or you may also email your request to QNTM@mzgroup.us or call Chris Tyson at (949) 491-8235.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (' Lucid '), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. ('Celly Nutrition'), led by industry veterans. Quantum BioPharma retains ownership of 22.95% (as of December 31, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as 'may', 'should', 'anticipate', 'expect', 'potential', 'believe', 'intend' or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Email: Zsaeed@quantumbiopharma.com Telephone: (833) 571-1811
Investor Relations Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 QNTM@mzgroup.us www.mzgroup.us
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
eXp Realty Dominates 2025 RealTrends Rankings With 757 Agents and Teams Honored
40 eXp Realty agents and teams break into the elite 'The Thousand' list, and the firm claims #1 spot for transactions nationwideBELLINGHAM, Wash., June 10, 2025 (GLOBE NEWSWIRE) -- eXp Realty®, 'the most agent-centric real estate brokerage on the planet™' and the core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced that a record-breaking 757 of its agents and teams have been named among the top real estate professionals in the country, according to the 2025 RealTrends Verified America's Best List. With fewer than 0.1% of agents qualifying nationwide, inclusion in the RealTrends rankings is a rare achievement that reflects exceptional production and service. Adding to the celebration, eXp Realty also ranked as the: #1 Brokerage in the U.S. by Transaction Sides #3 Brokerage in the U.S. by Sales Volume These accolades underscore eXp's continued dominance in the real estate space and its commitment to supporting agents through a robust cloud-based platform, best-in-class tools, and unparalleled collaboration opportunities. 'At eXp Realty, our agents are our greatest asset. Seeing 757 of our professionals earn recognition on the RealTrends lists is both humbling and energizing,' said Leo Pareja, CEO of eXp Realty. 'This success is a direct result of our commitment to providing agents with the tools, model, and culture they need to thrive. We are building something extraordinary, and this achievement is a powerful testament to the strength of our community.' With a mission to empower agents to build better businesses, eXp Realty continues to redefine what's possible in real estate, offering top-tier financial incentives, cutting-edge technology, and a globally connected network – all of which contribute to driving results for clients and professionals alike. About eXp World Holdings, Inc. eXp World Holdings, Inc. (Nasdaq: EXPI) (the 'Company') is the holding company for eXp Realty® and SUCCESS® Enterprises. eXp Realty is the largest independent real estate brokerage in the world, with over 81,000 agents across 27 countries. As a cloud-based, agent-centric brokerage, eXp Realty provides real estate agents industry-leading commission splits, revenue share, equity ownership opportunities, and a global network that empowers agents to build thriving businesses. For more information about eXp World Holdings, Inc., visit: SUCCESS® Enterprises, anchored by SUCCESS® magazine, has been a trusted name in personal and professional development since 1897. As part of the eXp ecosystem, it offers agents access to valuable resources to enhance their skills, grow their businesses, and achieve long-term success. For more information about SUCCESS, visit Safe Harbor and Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect the Company's and its management's current expectations but involve known and unknown risks and uncertainties that could impact actual results materially. These statements include, but are not limited to, statements regarding the anticipated success of agents or teams joining eXp Realty, future production goals or volume projections, and participation in or benefits derived from the Company's platform, tools, compensation model, or equity programs. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include real estate market fluctuations, changes in agent retention or recruitment, the Company's ability to expand successfully in international markets, competitive pressures, regulatory changes, and other risks detailed from time to time in the Company's Securities and Exchange Commission filings, including but not limited to the most recently filed Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. We do not undertake any obligation to update these statements except as required by law. Media Relations Contact:eXp World Holdings, Investor Relations Contact:Denise Garciainvestors@ A photo accompanying this announcement is available at
Yahoo
29 minutes ago
- Yahoo
GenAI Growth, Creative Cloud Pricing in Focus as Adobe Reports Q2
Adobe (NASDAQ:ADBE) is set to release its fiscal Q2 results on Thursday after markets close, and analysts say the spotlight will be squarely on the company's generative AI roadmap and competitive strategy. Morgan Stanley believes investor worries over Adobe's positioning in the AI space have contributed to the stock underperforming large-cap software peers by roughly 15 percentage points over the past three months. In a note Tuesday, analyst Keith Weiss said low expectations paired with potential gains in annual recurring revenue for Adobe's Digital Media business create a favorable risk-reward setup. The firm rates the stock Overweight with a $510 price target. Weiss also pointed to Adobe's push for innovation at the high end of its product line and more flexible pricing for smaller customers as key to boosting growth. Jefferies echoed that optimism, highlighting Adobe's 7% price hike for Creative Cloud renewals starting June 17. Analyst Brent Thill said the move should help offset headwinds from prior pricing changes and potentially lift 2026 results. Jefferies maintains a Buy rating and a $590 price target. Consensus estimates call for adjusted earnings of $4.97 per share on revenue of $5.8 billion. That compares with $5.08 in adjusted EPS and $5.71 billion in revenue from the previous quarter. Jefferies also flagged currency movements as a potential boost to revenue, estimating a 1 percentage point tailwind compared with current expectations of a neutral to slight headwind. This article first appeared on GuruFocus.
Yahoo
31 minutes ago
- Yahoo
Be Sure To Check Out Nasdaq, Inc. (NASDAQ:NDAQ) Before It Goes Ex-Dividend
Readers hoping to buy Nasdaq, Inc. (NASDAQ:NDAQ) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least one business day to settle. This means that investors who purchase Nasdaq's shares on or after the 13th of June will not receive the dividend, which will be paid on the 27th of June. The company's next dividend payment will be US$0.27 per share, and in the last 12 months, the company paid a total of US$1.08 per share. Based on the last year's worth of payments, Nasdaq has a trailing yield of 1.3% on the current stock price of US$85.65. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. So we need to investigate whether Nasdaq can afford its dividend, and if the dividend could grow. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. That's why it's good to see Nasdaq paying out a modest 43% of its earnings. Generally speaking, the lower a company's payout ratios, the more resilient its dividend usually is. Check out our latest analysis for Nasdaq Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings fall far enough, the company could be forced to cut its dividend. With that in mind, we're encouraged by the steady growth at Nasdaq, with earnings per share up 7.3% on average over the last five years. Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. In the last 10 years, Nasdaq has lifted its dividend by approximately 18% a year on average. We're glad to see dividends rising alongside earnings over a number of years, which may be a sign the company intends to share the growth with shareholders. Should investors buy Nasdaq for the upcoming dividend? It has been growing its earnings per share somewhat in recent years, although it reinvests more than half its earnings in the business, which could suggest there are some growth projects that have not yet reached fruition. We think this is a pretty attractive combination, and would be interested in investigating Nasdaq more closely. While it's tempting to invest in Nasdaq for the dividends alone, you should always be mindful of the risks involved. Case in point: We've spotted 1 warning sign for Nasdaq you should be aware of. If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
